Thursday, 5 November 2026European Markets

NRC GROUP Stock Was Up By 21.05% On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with NRC GROUP (NRC.OL) jumping 21.05% to kr4.60 on Thursday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI rose 0.76% to kr1,411.02, after two consecutive sessions in a row of losses, on what was a somewhat up trend trading session today.

NRC GROUP's last close was kr3.80, 72.06% below its 52-week high of kr13.60.

About NRC GROUP

NRC Group ASA, together with its subsidiaries, operates as a rail infrastructure company in Norway, Sweden, and Finland. It offers groundwork services, including excavations, transport, masses sorting, and ditching, as well as water and drainage systems; and signaling systems, digital telecom systems, electro, tracks, and station buildings and terminals, as well as catenary systems comprising wires, masts, switches, and return current systems. The company also provides complementary services, such as concrete work, recycling, demolition, and mass transport services; and specialized trackwork services. In addition, it offers railway construction and maintenance, civil construction, and environmental services; related infrastructure services, including bridges and crossings; and electrical installations for rail, light rail, and metro systems. The company was formerly known as Blom ASA and changed its name to NRC Group ASA in May 2015. NRC Group ASA was founded in 1966 and is headquartered in Lysaker, Norway.

Earnings Per Share

As for profitability, NRC GROUP has a trailing twelve months EPS of kr-11.46.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -41.7%.

More news about NRC GROUP (NRC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com